31 citations · 88 across the 12 of their papers we have counts for
14 papers
Exhausting the type I error level in event-driven group-sequential designs with a closed testing procedure for progression-free and overall survival
Moritz Fabian Danzer, Kaspar Rufibach, Jan Beyersmann +1
In oncological clinical trials, overall survival (OS) is the gold-standard endpoint, but long follow-up and treatment switching can delay or dilute detectable effects. Progression-…
Survival analysis for AdVerse events with VarYing follow-up times (SAVVY): summary of findings and a roadmap for the future of safety analyses in clinical trials
Kaspar Rufibach, Jan Beyersmann, Tim Friede +2
The SAVVY project aims to improve the analyses of adverse events (AEs) in clinical trials through the use of survival techniques appropriately dealing with varying follow-up times…
Oncology clinical trial design planning based on a multistate model that jointly models progression-free and overall survival endpoints
Alexandra Erdmann, Jan Beyersmann, Kaspar Rufibach
When planning an oncology clinical trial, the usual approach is to assume proportional hazards and even an exponential distribution for time-to-event endpoints. Often, besides the…
Design aspects of COVID-19 treatment trials: Improving probability and time of favourable events
Jan Beyersmann, Tim Friede, Claudia Schmoor
As a reaction to the pandemic of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a multitude of clinical trials for the treatment of SARS-CoV-2 or the resulting c…
Survival analysis for AdVerse events with VarYing follow-up times (SAVVY) -- estimation of adverse event risks
Regina Stegherr, Claudia Schmoor, Jan Beyersmann +12
The SAVVY project aims to improve the analyses of adverse event (AE) data in clinical trials through the use of survival techniques appropriately dealing with varying follow-up tim…
Survival analysis for AdVerse events with VarYing follow-up times (SAVVY) -- comparison of adverse event risks in randomized controlled trials
Kaspar Rufibach, Regina Stegherr, Claudia Schmoor +12
Analyses of adverse events (AEs) are an important aspect of the evaluation of experimental therapies. The SAVVY (Survival analysis for AdVerse events with Varying follow-up times)…